Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis

Age and Ageing

Volumn 41, Issue 5, 2012, Pages 681-684

  Ali, Ali ^a   Bailey, Claire ^a   Abdelhafiz, Ahmed H ^a  

^a ROTHERHAM GENERAL HOSPITAL   (United Kingdom)

Author keywords

Anticoagulation; Cost; Non valvular atrial fibrillation

Indexed keywords

DABIGATRAN; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING DISORDER; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFECT; DRUG SAFETY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; INTERVIEW; MAJOR CLINICAL STUDY; MALE; NON VALVULAR ATRIAL FIBRILLATION; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; STROKE; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; COSTS AND COST ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; STROKE; TREATMENT OUTCOME; WARFARIN;

EID: 84865533964     PISSN: 00020729     EISSN: 14682834     Source Type: Journal    
DOI: 10.1093/ageing/afs017     Document Type: Article

References (12)

1. Singer DE, Albers GW, Dalen JE et al. Antithrombotic therapy in atrial fibrillation: the seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest 2004; 126 (Suppl): 429s-56s.
2. Wang TJ, Massaro JM, Levy D et al. A risk score for predicting stroke or death in individuals with new onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 2003; 290: 1049-56.
3. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-67.
4. Boulanger L, Kim J. Patterns of use of antithrombotic therapy and quality of anticoagulation among patients with nonvalvular atrial fibrillation in clinical practice. Int J Clin Pract 2006; 60: 258-64.
5. Connnolly SJ, Ezekowitz MD, Yusuf S et al. The RE-LY Steering Committee and Investigators: dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
6. Shah SV, Gage BF. Cost effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation 2011; 123: 2562-70.
7. Abdelhafiz AH, Wheeldon NM. Use of resources and cost implications of stroke prophylaxis with warfarin for patients with nonvalvular atrial fibrillation. Am J Geriatr Pharmacother 2003; 1: 53-60.
8. O'Donoghue J, Goulding L, Allen G. Consumer price inflation since 1750. Eco Tren 2004; 604: 38-46.
9. National Institute for Health and Clinical Excellence. Final appraisal determination-dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation. Issue date: October 2011.
10. Freeman JV, Zhu RP, Owens DK et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011; 154: 1-11.
11. Wallentin L, Yusuf S, Ezekowitz MD et al. RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalized ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376: 975-83.
12. Gage BF, Waterman AD, Shannon W et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-70.